UCB commences new Cimzia study for rheumatoid arthritis

UCB has announced the commencement of a new clinical study that will assess the safety and efficacy of Cimzia in a new indication against rheumatoid arthritis.

The phase III C-Early trial will evaluate a combination therapy involving Cimzia and methotrexate for adults with early, progressive and active moderate-to-severe rheumatoid arthritis, who have not previously been treated with disease-modifying antirheumatic drugs.

It will also offer insight into whether the frequency of certolizumab pegol administration can be reduced after sustained low disease activity has been achieved.

European League Against Rheumatism guidance has suggested that achieving disease control at the earliest possible stage is a desirable outcome, as this can improve long-term outcomes.

Professor Dr Iris Loew-Friedrich, chief medical officer and executive vice-president at UCB, said: "We are pleased to announce the start of this study, which … reflects our continuing commitment to improving the lives of patients at all stages of this severe progressive disease."

Earlier this month, UCB published data from a recent Cimzia study that showed the benefits of the drug as a treatment for psoriatic arthritis.